Pfizer shares fell 1% in after-hours trading

Previously, the company announced the Phase III clinical trial results for its drug Sigvotatug Vedotin, which showed that the drug failed to significantly improve overall survival in patients. This outcome delivered a setback to Pfizer’s highly anticipated oncology pipeline. The market reacted promptly to this news, testing investor confidence. The stock price volatility reflected the market’s heightened sensitivity to R&D progress and a reassessment of future revenue potential. Despite this setback, Pfizer’s overall R&D pipeline remains extensive. The company stated it will continue to advance other ongoing projects. However, the failure of this key study undoubtedly adds uncertainty to the competitive landscape in the related field and underscores the inherent high risks of new drug development.